Health regulator authorizes Indian company to sell first generic Ozempic in Canada
Health Canada has authorized Dr. Reddy’s Laboratories Ltd. to sell the first generic version of Ozempic in Canada. This approval follows a delay of nearly four months since generic Ozempic became legal in the country. The introduction of the generic drug is expected to significantly reduce costs for patients and health insurance plans.
- ▪Dr. Reddy’s Laboratories Ltd. is the first company approved to sell a generic version of Ozempic in Canada.
- ▪The generic version is expected to offer discounts of up to 65 percent for patients and health insurance plans.
- ▪Currently, over a million Canadians take semaglutide, and the number is expected to grow with the availability of generics.
The Globe and Mail publishes from Canada and files mainly under world. We currently carry 1,935 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Globe and Mail |
| Canonical URL | https://www.theglobeandmail.com/business/economy/article-generic-ozempic-glp1-approved-health-canada/ |
| Publication time | Tue, 28 Apr 2026 21:06:20 +0000 |
| Retrieval time | 2026-04-28T21:14:39.821Z |
| Last seen | 2026-04-28T21:14:39.821Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 4ta702k11v-p |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Open this photo in gallery:A doctor in Mumbai displays the Ozempic GLP-1 self-injectable at a clinic.INDRANIL MUKHERJEE/AFP/Getty ImagesShareSave for laterPlease log in to bookmark this story.Log InCreate Free AccountIndian pharmaceutical company Dr. Reddy’s Laboratories Ltd. has become the first drug maker approved by Health Canada to sell a generic version of the blockbuster drug Ozempic.The authorization comes nearly four months after generic Ozempic became legal in Canada, a delay longer than many manufacturers, physicians and patients had been hoping for.The development means those taking the drugs will potentially receive significant discounts, eventually as much as 65 per cent off, as will public and private health insurance plans that have seen costs balloon because of growing…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Globe and Mail.
Discussion
0 commentsMore from The Globe and Mail
